CIK 0001649094 · Large accelerated filer
Vaxcyte, Inc.
Sign in to watch- Ticker
- PCVX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464233385
- Phone
- 650-837-0111
- Business address
- 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070
- Former names
- SutroVax, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,185,988
- in 8 filings, $4.8M under 10b5-1 plans
Net −$5,185,988. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-23 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −119 | $77.56 | $9K | 375,814 |
| 2024-02-23 | PICKERING GRANT CHIEF EXECUTIVE OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 60,225 | ||
| 2024-02-20 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise 10b5-1 | +8,000 | $5.35 | $43K | 87,474 |
| 2024-02-20 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −4,909 | $74.08 | $364K | 82,565 |
| 2024-02-20 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −2,751 | $75.17 | $207K | 79,814 |
| 2024-02-20 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −340 | $75.80 | $26K | 79,474 |
| 2024-02-20 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 376,827 | ||
| 2024-02-15 | Wassil Jim CHIEF OPERATING OFFICER | Option exercise | +27,917 | $2.42 | $68K | 203,852 |
| 2024-02-15 | Wassil Jim CHIEF OPERATING OFFICER | Option exercise · Stock Option (right to buy) | −27,917 | 62,638 | ||
| 2024-02-01 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Option exercise 10b5-1 | +1,667 | $21.41 | $36K | 22,377 |
| 2024-02-01 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −212 | $72.22 | $15K | 22,165 |
| 2024-02-01 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −638 | $73.17 | $47K | 21,527 |
| 2024-02-01 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −343 | $74.11 | $25K | 21,184 |
| 2024-02-01 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −474 | $75.39 | $36K | 20,710 |
| 2024-02-01 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,667 | 191,666 | ||
| 2024-02-01 | Wassil Jim CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +3,000 | $2.42 | $7K | 178,935 |
| 2024-02-01 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −527 | $72.18 | $38K | 178,408 |
| 2024-02-01 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −1,056 | $73.35 | $77K | 177,352 |
| 2024-02-01 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −467 | $74.14 | $35K | 176,885 |
| 2024-02-01 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −950 | $75.28 | $72K | 175,935 |
Page 33 of 39 · 764 trades